Edwards Lifesciences Corporation · NYSE:EW
Edwards Lifesciences — Shareholder Meeting (March 2024)
14 slides from Edwards Lifesciences's shareholder meeting presentation, Mar 26, 2024
Slide 1: Schedule 14A Proxy Statement
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy
Slide 2: Edwards Lifesciences Spring 2024 Stockholder Presentation
Edwards Lifesciences Spring 2024 Stockholder Presentation
Slide 3: Cautionary Statement and Use of Non-GAAP Financial Measures
Cautionary Statement and Use of Non-GAAP Financial Measures 2 ▪ This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend the forward-looking stateme
Slide 4: We Request Your Support at the 2024 Annual Meeting of Stockholders
We Request Your Support at the 2024 Annual Meeting of Stockholders 3 Proposal 1. FOR Election of Eight Director Nominees Proposal 2. FOR Advisory Vote to Approve Named Executive Officer Compensation Proposal 3. FOR Ratification of Appointment of Independent Registered Public Accounting Firm Proposal
Slide 5: Our Credo
Our Credo At Edwards Lifesciences, we are dedicated to providing innovative solutions for people fighting cardiovascular disease. Through our actions, we will become trusted partners with customers, colleagues, and patients – creating a community unified in its mission to improve the quality of life
Slide 6: Edwards Lifesciences at a Glance
Edwards Lifesciences at a Glance 5 COMPANY OVERVIEW UNIQUE INNOVATION STRATEGY Lead groundbreaking standards of care through trusted relationships Leadership Singular focus on the large unmet needs of structural heart patients Focus Pioneer breakthrough technologies with compelling evidence Innovati
Slide 7: Approach to Financial Value Creation Has Produced Long-Term Shareholder Returns
Edwards Lifesciences SPSIHE S&P 500 Edwards’ Approach to Financial Value Creation has Produced Long-Term Shareholder Returns 6 2013-2023 Total Shareholder Return(1) 1 Capital IQ, reflecting performance from December 31, 2012 through December 29, 2023 2 S&P Healthcare Equipment Select Industry Index
Slide 8: Clear Strategy for Sustainable Growth
Clear Strategy for Sustainable Growth 7 Building momentum Key milestones and strong financial performance 2024 Faster growth Achievement of new indications and launch of new technologies following spin-off 2025-2026 Expanding opportunities Continued healthy momentum driven by new indications, new te
Slide 9: Strong Leadership Structure to Guide Continued Company Growth
Strong Leadership Structure to Guide Continued Company Growth 8 As part of a thoughtful transition, Mr. Mussallem and Ms. Marsh will not be standing for re-election at the 2024 Annual Meeting and Mr. Valeriani will be appointed Chairman of the Board The Board is confident in the go-forward structure
Slide 10: Well-Balanced and Diverse Board
Well-Balanced and Diverse Board(1) 9 Medical Technology Industry Experience International Executive Experience Corporate Governance Risk Management Risk Oversight Executive Leadership Innovation and Technology Corporate Responsibility Operations Management Corporate Strategy and Development IT and C
Slide 11: CEO Pay Elements and Performance Measures
CEO Pay Element Components Corporate Performance Measures & Rationale Base Salary Cash ▪ Attract and retain executives Annual Cash Incentive(1) Financial Measurement ▪ Based on underlying revenue growth (50%), adjusted earnings per share (30%), and adjusted free cash flow (20%) targets set at the be
Slide 12: Robust Corporate Impact Oversight and Disclosure
Robust Corporate Impact Oversight and Disclosure 11 CEO Compensation & Governance Committee Audit Committee Senior Vice President, Associate General Counsel and Corporate Secretary Board of Directors Transforming patient lives with breakthrough medical technologies Excelling as a trusted partner thr
Slide 13: Commitment to Stockholder Engagement and Responsiveness
12 Commitment to Stockholder Engagement and Responsiveness We have consistently contacted stockholders holding >50% of outstanding stock each year since 2015 to discuss topics of interest with active participation from an independent director 2 0 2 4 2 0 1 9 2 0 1 5 DISCUSSION TOPICS Governance feat
Slide 14: Slide 14
Edwards Lifesciences — Shareholder Meeting (March 2024) on 6ix